Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Kognitive strategier til optimering af hjernesundhed og håndtering af transgenerationelle vaskulære risikofaktorer efter slagtilfælde (CHAMPS-TR)

16. november 2026 opdateret af: University of New Mexico

Kognitive strategier til optimering af hjernesundhed og håndtering af transgenerationelle vaskulære risikofaktorer efter slagtilfælde (CHAMPS for transgenerationel risiko)

People living with the cognitive effects of stroke are at risk for recurrent stroke and further cognitive decline. Also problematic is that stroke risk clusters in families and biological family members of people who have ischemic stroke may also be at increased risk of stroke and/or cognitive decline. The primary goal of this study is to test the feasibility of a virtually delivered cognitive strategy training and health coaching program to reduce vascular risk and promote brain health in persons with stroke and their biological family members.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

CHAMPS for Transgenerational Risk (TR) (Cognitive strategies for optimizing brain Health And Managing transgenerational vascular risk factors Post-Stroke), a feasibility trial for preventing stroke and improving cognitive outcomes in persons with stroke and their families. Stroke is used as a vector to identify both persons with post-stroke cognitive impairment and dementia (PSCID)and a targeted family member who may be at risk and could benefit from vascular risk reduction intervention. The investigators integrate the concept of a "teachable moment" where health events can lead to behavior change by targeting family members who are stroke-free but may have vascular risk factors putting them at risk for stroke and vascular cognitive impairment (VCI) in the future. Recognizing that people with stroke frequently encounter barriers to community mobility, the proposed trial will be offered virtually to give even those with difficulty accessing the community an equitable opportunity to participate in clinical research.

In this feasibility trial, the investigators will pilot test the CHAMPS-TR intervention which includes vascular risk reduction coaching and a metacognitive problem-solving protocol which contains guided discovery, goal setting, and strategy training. Index persons with stroke and targeted family members (i.e., biological child, younger sibling) who may be at heightened risk for stroke and VCI will receive the CHAMPS intervention which will be delivered remotely. Participants will be split into two arms and either receive the virtual CHAMPS-TR intervention or CHAMPS-TR intervention plus remotely-supervised transcranial Direct Current Stimulation (RS-tDCS) based on eligibility and preference. tDCS is a minimally invasive brain stimulation technique that may augment the effects of cognitive interventions alone. It has strong evidence in stroke rehabilitation and RS-tDCS is a feasible approach in those with stroke and other clinical populations. The overarching goal of this project is to rigorously test the custom-tailored intervention for families impacted by ischemic stroke.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

40

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • New Mexico
      • Albuquerque, New Mexico, Forenede Stater, 87131
        • University of New Mexico Health Sciences Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. primary diagnosis of acute ischemic stroke,
  2. impairment of cognitive function (score >1 on Quick Executive Interview - telephone screener),
  3. absence of severe aphasia (score of 0 or 1 on NIH Stroke Scale),
  4. absence of pre-stroke dementia (client report),
  5. absence of major anxiety and depressive disorder (PHQ-9, GAD-7),
  6. absence of drug and alcohol misuse within 3 months of study (AUDIT, DAST),
  7. greater than 40 years of age,
  8. having a potential family member who meets targeted family member criteria,
  9. eligible for MRI and Remote Supervised-transcranial direct current stimulation (RS-tDCS) if in CHAMPS-TR plus RS-tDCS (e.g., not pregnant; no intracranial metal implants; no skin lesions on target sites for stimulation; no severe cardiopulmonary, renal or hepatic diseases; no pacemakers; no underlying medical reason for not engaging in MRI or tDCS).

The targeted family member will be:

  1. a minimum of 18 years of age,
  2. biological kin of person with stroke,
  3. absence of dementia (client report),
  4. absence of major anxiety and depressive disorder (PHQ-9, GAD-7),
  5. absence of drug and alcohol misuse within 3 months of study (AUDIT, DAST),
  6. greater than 18 years of age, and
  7. having a sibling or parent who had an ischemic stroke

Exclusion Criteria:

For all participants:

  1. not English speaking, reading, and understanding, and
  2. no access to video-conference software on a computer or smart device

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: CHAMPS-TR

Persons with stroke and a targeted biological family member will receive the CHAMPS intervention including vascular risk reduction coaching and cognitive strategy training.

Persons with stroke ( n=20) and at least 1 targeted family member (TFM) (n=20) will engage with the CHAMPS-TR protocol which involves 10 virtual intervention sessions (bi-weekly for 5 weeks) with key elements including metacognitive problem-solving training (i.e., goal setting, guided discovery, strategy development) and vascular risk reduction coaching building on existing American Heart Association (AHA) LE8 content. Probands that are eligible for RS-tDCS (n=10) will receive 5x weekly (weeks 2-5) RS-tDCS applied to the left dorsolateral prefrontal cortex (DLPFC).

Eksperimentel: CHAMPS TR plus remotely supervised transcranial direct current stimulation (RS-tDCS)

Persons with stroke and a targeted biological family member will receive the CHAMPS intervention including vascular risk reduction coaching and cognitive strategy training. Persons with stroke will also receive RS-tDCS.

Persons with stroke ( n=20) and at least 1 targeted family member (TFM) (n=20) will engage with the CHAMPS-TR protocol which involves 10 virtual intervention sessions (bi-weekly for 5 weeks) with key elements including metacognitive problem-solving training (i.e., goal setting, guided discovery, strategy development) and vascular risk reduction coaching building on existing American Heart Association (AHA) LE8 content. Probands that are eligible for RS-tDCS (n=10) will receive 5x weekly (weeks 2-5) RS-tDCS applied to the left dorsolateral prefrontal cortex (DLPFC).

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
American Heart Association Life's Essential 8 Metrics
Tidsramme: baseline, up to 7 weeks, and up to 24 weeks

metric scores for vascular risk; score is calculated on a 0-100 scale where 100 is ideal

baseline, up to 7 weeks, and up to 24 weeks
Cardiovascular risk factors, Aging, and Incidence of Dementia (CAIDE)
Tidsramme: baseline, up to 7 weeks, and up to 24 weeks

Risk profile score for cognitive decline; score is composed of weightings by reference to age, sex, education, systolic blood pressure, BMI, total cholesterol, and physical activity. Scores range from 0-15 with higher scores indicating greater risk.

baseline, up to 7 weeks, and up to 24 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Oral Trail Making Test Part B
Tidsramme: baseline and up to 24 weeks

Test of mental sequencing and switching; score with total number of seconds to complete up to 300, total number of errors, and total correct

baseline and up to 24 weeks
Number Span Test Forward and Backward
Tidsramme: baseline and up to 24 weeks

Test of working memory; scored with number of correct trials (0-14), and longest span forward (0, 3-9) and longest span backward (0, 2-8). Higher numbers are greater number of correct items.

baseline and up to 24 weeks
Multiple Errands Test Home Version
Tidsramme: baseline and up to 24 weeks

Test of executive function impact on everyday life; total score of 0-14 with higher levels indicating less impairment; additional sub-scores for errors made and strategies used using total scores.

baseline and up to 24 weeks
Mark VCID2 Clinical Cognitive Assessment Battery
Tidsramme: baseline and up to 24 weeks

Test of cognitive impairment and dementia; total scores on all sub-scores for each included measure.

baseline and up to 24 weeks
PROMIS Self-Efficacy for Managing Medications
Tidsramme: baseline, up to 7 weeks, and up to 24 weeks

Test of self efficacy for managing medications; scoring with item-level calibrations using HealthMeasures Scoring Service

baseline, up to 7 weeks, and up to 24 weeks
PROMIS Self-Efficacy for Managing Symptoms
Tidsramme: baseline, up to 7 weeks, and up to 24 weeks

Test of self efficacy for managing symptoms; scoring with item-level calibrations using HealthMeasures Scoring Service

baseline, up to 7 weeks, and up to 24 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

12. oktober 2023

Primær færdiggørelse (Faktiske)

30. juni 2026

Studieafslutning (Anslået)

1. februar 2027

Datoer for studieregistrering

Først indsendt

14. juni 2024

Først indsendt, der opfyldte QC-kriterier

26. juni 2024

Først opslået (Faktiske)

28. juni 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • HRRCID 23-332

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Data Sharing Plan

The investigators will share data collected in this project:

At National Scientific Meetings: The investigators expect to share results from the data at two conferences/scientific meetings a year such as the American Congress of Medical Rehabilitation Conference, the RESNA conference, the American Occupational Therapy Conference, and Aging Conferences.

Through Publication in Scientific Journals: the investigators expect to publish 1-2 journal articles a year where data from the proposed project will be shared with no subject identifiers.

Data to be shared includes de-identified: MRI data, feasibility data, self-efficacy scores, vascular risk factor scores, cognitive/executive function scores

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .